A Phase Ib, Open-label, Multicenter, Dose Escalation and Expansion Study, to Evaluate the Safety, Pharmacokinetics and Activity of INC280 in Combination With Cetuximab in c-MET Positive CRC and HNSCC Patients Who Have Progressed After Anti-EGFR Monoclonal Antibody Therapy.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs Capmatinib (Primary) ; Cetuximab
- Indications Colorectal cancer; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 10 Dec 2017 This trial has been completed in Germany (end date:2017-01-20).
- 21 Jul 2017 Status changed from suspended to discontinued.